Orchid Pharma licenses Exblifep across nine Latin American markets
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Orchid Pharma signed a licensing and supply agreement with Laboratorio Libra for Exblifep, a cefepime and enmetazobactam antibiotic. Libra receives exclusive rights to register, import and market it in nine Latin American countries, while Orchid manufactures and supplies it. Commercial launches require local regulatory approvals. The partners see a potential USD 80 million opportunity over 10 years based on projected demand.
The deal could add export sales and broaden Exblifep's reach, but the USD 80 million estimate depends on regulatory approvals and projected demand.